Lohmann Rauscher (LR): Personnel Change in Executive Board of LR

Food and Healthcare Press Releases Friday January 26, 2018 09:15
VIENNA and RENGSDORF, Germany--26 Jan--PRNewswire/InfoQuest

In January 2018, a change in the Executive Board of manufacturer and supplier of medical devices, Lohmann & Rauscher (L&R), took place after the former Chief Commercial Officer, Markus Sebastian, had resigned.

The Advisory Board and the CCO mutually agreed that Markus Sebastian is going to leave the Lohmann & Rauscher Corporate Group by the end of January 2018 to pursue new tasks and face new challenges.
Responsibility for the business unit Marketing & Sales will be assumed by Dipl.-Ing. Wolfgang Suessle, President & CEO, on a transitional basis.
Reprint free of charge - specimen copy requested
Lohmann & Rauscher Corporate Group

Lohmann & Rauscher (L&R) is a leading international supplier of high-quality medical devices and hygiene products ranging from conventional dressing material to modern treatment and nursing systems. Created in 1998 through the merger of Lohmann (founded in 1851) and Rauscher (founded in 1899), L&R has more than 160 years' expertise as a reliable solution provider for its customers.

With 4,600 employees, 44 corporate subsidiaries and shareholdings and more than 130 select partners, the company is active in all of the world's key markets. The L&R Group was able to realize a sales of EUR604,2 million in 2017. The L&R headquarters are located in Rengsdorf (Germany) and Vienna (Austria).

L&R's entrepreneurial spirit is reflected in the Group's claim of People.Health.Care.: the human, the health, and the care for both.
Further information on Lohmann & Rauscher (L&R) can be found at:
http://www.lohmann-rauscher.com
Press Contact:
Lohmann & Rauscher International GmbH & Co. KG
Public Relations
Sabrina Klein
Johann-Schorsch-Gasse 4 1140 Vienna
Tel.: +43-1-57670-386 Fax DW: 9386
E-Mail: Sabrina.Klein@at.LRmed.com
http://www.lohmann-rauscher.com
Source: Lohmann & Rauscher

Latest Press Release

Pivotal Phase III Data for BAVENCIO(R) (avelumab) Plus INLYTA(R) (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine

- JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 in patients regardless of PD-L1 expression - US FDA has granted Priority Review to BAVENCIO plus INLYTA for patients with advanced renal cell...

ISABS เตรียมจัดการประชุมว่าด้วยการแพทย์ส่วนบุคคลที่โครเอเชีย พร้อมเชิญเจ้าของรางวัลโนเบลร่วมบรรยาย

International Society for Applied Biological Sciences (ISABS) ร่วมกับ Mayo Clinic และ St. Catherine Hospital เตรียมจัดการประชุม "ISABS Conference on Forensic and Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine" ครั้งที่ 11...

ISABS: Personalized Medicine Conference With Nobel Laureates to Be Held in Split, Croatia

International Society for Applied Biological Sciences (ISABS), Mayo Clinic and St. Catherine Hospital are organizing "11th ISABS Conference on Forensic and Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine"(http://www.isabs.net)...

Beijing Intellectual Property Court Confirms Judgment Against Wuxi Hisky Medical for Patent Infringement of Technology Used for Echosens# FibroScan(R), Imposes Damages Orders Halt to Manufacturing and Sales

Echosens, an innovative high-technology company offering the FibroScan family of products dedicated to assessment of chronic liver disease, today announces that the Beijing Intellectual Property Court has confirmed judgment against Wuxi Hisky Medical,...

5 Ways to Set Healthy Grocery Shopping Habits in 2019

By Susan Bowerman, M.S., RD, CSSD, CSOWM, FAN, Senior Director, Worldwide Nutrition Education and Training Make your daily staples as healthy as you can. Small changes in the foods you eat every day can add up to big rewards. The holidays are over, and...

Related Topics